Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic ...(patient-friendly oral dosing regimen;lim...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
Date:1/29/2008
patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.
About Ardea Biosciences, Inc.
Ardea Biosciences of Carlsbad, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of gout. In oncology, the Company is investigating a mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to, statements
regarding: Ardea's goals, including the expected properties and benefits of
RDEA806, RDEA119 and its other compounds and the results of clinical and
other studies. Risks that contribute to the uncertain nature of the
forward-looking statements include: risks related to the outcomes of
preclinical and clinical trials, risks related to regulatory approvals,
delays in commencement of preclinical and clinical tests, and costs
associated with internal development and in-licensing activities. These and
other risks and uncer
'/>"/>
| SOURCE Ardea Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Ardea Biosciences Announces $40 Million Private Placement
2. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences Announces Changes to Research Management
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
7. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
9. YM BioSciences provides update on AeroLEF(TM) clinical development program
10. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
11. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
Post Your Comments:
(Date:11/21/2008)...S and New York, Nov. 21 ...Systems Incorporated (Nasdaq: IMCL ) today,anno...announced tender offer,by Lilly,s wholly-owned su...,outstanding shares of ImClone at a price of $70.0...midnight EST, on Thursday, November 20, 2008. , ...
(Date:11/21/2008)...ov. 21 Intellect Neuros...iopharmaceutical company focused on development of...tment and prevention of Alzheimer,s disease releas... Dr. Daniel Chain, its Chairman and CEO. , ,...e to serve as Chairman and CEO of Intellect Neuros...
(Date:11/20/2008)...J., Nov. 20 Wyeth (NYSE:....D., 57, has been promoted to President,Technica.... Kamarck will be,responsible for all aspects of ..., including its Pharmaceutical, BioPharma, Vaccine...succeeds Charles Portwood, 58, who has been,appoi...
(Date:11/20/2008)...Nov. 20 Sigma-Aldrich (N...e of MISSION(R) In VIVO QUALITY and iScale,Oligos...Oligos(TM) siRNA are,expected to allow researcher...,research with the highest purity and quality siR...hese siRNA are believed to be well suited to targe...
Breaking Biology Technology:Lilly Completes Cash Tender Offer for ImClone Systems 2Lilly Completes Cash Tender Offer for ImClone Systems 3Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 2Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 3Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 4Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 5Wyeth Names Michael Kamarck President, Technical Operations & Product Supply 2Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2[0] Lilly Completes Cash Tender Offer for ImClone Systems[0] Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO[0] Wyeth Names Michael Kamarck President, Technical Operations & Product Supply[0] Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
...issue, Wisconsin Technology Network launches a spe...tion (RFID) technology. While the technology is no...act on business. It is from that perspective that ...es written by WTN writers and contributed by Wisco...nsin, businesses and organizations are steeping th...
... . Implementation of a controversial web-based so... the University of Wisconsin System should proceed...t recommends. , ,The UW-Madison Lawson Assessment ...e to work with St. Paul, Minn.-based Lawson Softw...nefits System (ABPS) project, which was put on hol...
...nc. of Berlin, Germany plans to acquire Roentec ...y with annual revenues of $6-7 million, based in B..., but the acquisition is expected to close in the ...merican headquarters in Madison, Wis. The worldwid...eater than $150 million per year, and Bruker AXS s...
...- Wisconsin is 27 th in the nation in its friendl...ng to the Small Business & Entrepreneurship Counc...week. , ,The SBE Council is a national nonpartisan...tered in Washington, D.C. , ,According to SBE Coun...f the study, "The ,Small Business Survival Index,...
Other Biology Technology:RFID starting to make real impact on business 2RFID starting to make real impact on business 3Report gives nod to controversial Lawson project 2Report gives nod to controversial Lawson project 3Report gives nod to controversial Lawson project 4(Date:11/20/2008)... OAK RIDGE, Tenn., Nov. 20, 2008 -- A team led by ...,s Oak Ridge National Laboratory received the pres...ACM) Gordon Bell Prize Thursday after attaining th...mputing application. , Schulthess is group leade...and recently accepted a position as director of th...
(Date:11/20/2008)... Fighting virtual crime, treating an ageing popula...ises, will be the focus of a 20 million ($30.4 mil...g and Physical Sciences Research Council (EPSRC), ...ogy and Biological Sciences Research Council (BBSR...ntres in areas where world-class scientific breakt...
(Date:11/19/2008)... Larvae of marine invertebrates worms, sponges, j... consist of no more than two cells: a photorecepto...led eyespots, resemble the ,proto-eyes, suggested ...nimal evolution. They cannot form images but allow...ability is crucial for phototaxis the swimming to...
(Date:11/19/2008)... Here is the latest American Chemical Society (ACS... 36 peer-reviewed journals and Chemical & Enginee...or the American Chemical Society as the source for...E RELEASE EXCEPT ARTICLE #5, which is embargoed fo... , ARTICLE #1 FOR IMMEDIATE RELEASE , Microca...
Breaking Biology News(10 mins):ORNL supercomputer simulation wins prize for fastest-running science application 2ORNL supercomputer simulation wins prize for fastest-running science application 3£20 million to fight virtual crime and treat our aging population 2£20 million to fight virtual crime and treat our aging population 3Uncovering secrets of life in the ocean 2American Chemical Society's Weekly PressPac -- Nov. 19, 2008 2American Chemical Society's Weekly PressPac -- Nov. 19, 2008 3American Chemical Society's Weekly PressPac -- Nov. 19, 2008 4American Chemical Society's Weekly PressPac -- Nov. 19, 2008 5American Chemical Society's Weekly PressPac -- Nov. 19, 2008 6American Chemical Society's Weekly PressPac -- Nov. 19, 2008 7American Chemical Society's Weekly PressPac -- Nov. 19, 2008 8Cold Weather Can Increase Heart Disease Risks 3761 1Cold Weather Can Increase Heart Disease Risks 3761 2Photo 3A Introducing a New Line of Baby and Toddler Shirts that Can Help Protect Innocent Babies During Flu Season 3756 1Photo 3A Introducing a New Line of Baby and Toddler Shirts that Can Help Protect Innocent Babies During Flu Season 3756 2National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti Aging Applications 1276 1National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti Aging Applications 1276 2National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti Aging Applications 1276 3IsoTis Reports Interim Results of Vote for Integra Merger 1274 1IsoTis Reports Interim Results of Vote for Integra Merger 1274 2IsoTis Reports Interim Results of Vote for Integra Merger 1274 3IsoTis Reports Interim Results of Vote for Integra Merger 1274 4... after many surgical procedures. In particular, Me...which has been found in many healthcare settings, ... study published in the April issue of the America... infections in the eyes of 12 patients after refra... infectious keratitis following refractive surgery...
...children who sleep less, and they are less likely ...s later. That’s one of the major findings of a new...e of the journal Child Development. , Conducted by... looked at 2,281 children from a nationally repres...ement of the Panel Survey of Income Dynamics. The ...
....5 million research program at Iowa State Universi...ce biorenewable fuels. The grant is part of Conoco...ith major universities to produce viable solutions...hillips will make an initial $1.5 million grant in...tional grants of $3 million per year for seven yea...
...ory diseases such as viral influenza. For elderly ...s. What is more, the flu vaccine is not as effecti...le. The reason for this is that with age the fire ... the case is largely unknown. An international EU ...ing which aims at shedding light on this. Among ot...
Other Biology News:Drug-resistant bacterial infections serious complication after corrective eye surgery 2Children who sleep more weigh less 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 3Fighting influenza & co. with 40,000 blood samples 2Fighting influenza & co. with 40,000 blood samples 3Rat Hepatocytes (RH) (>3,000,000 cells)
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)
...on Buffer is a concentrated formulation of a rinsi...ary action technology, as well as for manual immun...David Brigati M.D., Department of Pathology, Unive...is recommended for all the rinsing steps performed...
Phytohemagglutinin from Invitrogen
Biology Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |